---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-027987"
form_type: "8-K"
ticker: null
cik: "0001693011"
company_name: "Inozyme Pharma, Inc."
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T01:20:07.250366+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Inozyme Pharma amends bylaws for universal proxy rules; shareholders re-elect three directors

## Summary
- Bylaw amendments enhance disclosure for stockholder nominations and require compliance with SEC Rule 14a-19 universal proxy.
- Stockholders re-elected Martin Edwards, Lynne Sullivan, and Douglas Treco as Class III directors for three-year terms.
- Ratification of Ernst & Young as independent auditor for FY2023 passed with 36,729,818 votes for vs. 10,739 against.
- Other changes include eliminating stockholder list requirement during meetings, remote meeting adjournment for technical failures, and emergency board provisions.

## SEC filing metadata
- accession: 0000950170-23-027987
- form_type: 8-K
- cik: 0001693011
- company_name: Inozyme Pharma, Inc.
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1693011/000095017023027987/0000950170-23-027987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1693011/000095017023027987/inzy-20230613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-027987
- JSON: https://secwatch.observer/filing/0000950170-23-027987.json
- Plain text: https://secwatch.observer/filing/0000950170-23-027987.txt

## Key facts
- Governance Changes
  Inozyme Pharma, Inc.: Approved an amendment and restatement of the company's bylaws, effective immediately, including changes related to universal proxy rules, stockholder nominations, meeting procedures, and emergency provisions (effective 2023-06-13).
  - Change: bylaw amendment
  - Effective: 2023-06-13
  source text: On June 13, 2023, the Board of Directors (the “Board”) of Inozyme Pharma, Inc. (the “Company”) approved an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1693011/000095017023027987/0000950170-23-027987-index.htm
- Shareholder Votes
  Inozyme Pharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-13 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 was ratified. The results of the stockholders’ votes with respect to such ratification were as follows: Votes For: 36,729,818 Votes Against: 10,739 Votes Abstaining: 371 Broker Non-Votes: —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1693011/000095017023027987/0000950170-23-027987-index.htm
- Shareholder Votes
  Inozyme Pharma, Inc. shareholders approved Election of three Class III directors at the 2023-06-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: The following three nominees were elected to the Board as Class III directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders. The results of the stockholders’ votes with respect to the election of such Class III directors were as follows: Votes For Votes Withheld Broker Non-Votes Martin Edwards 18,800,004 9,699,208 8,241,716 Lynne Sullivan 27,636,274 862,938 8,241,716 Douglas Treco 28,377,236 121,976 8,241,716
  evidence_url: https://www.sec.gov/Archives/edgar/data/1693011/000095017023027987/0000950170-23-027987-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.